

Taimei

太美医疗科技

浙江太美醫療科技股份有限公司
Zhejiang Taimei Medical Technology Co., Ltd.

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

Stock Code 股份代號：2576




2025

INTERIM REPORT

中期報告

Contents

2	Corporation Information
4	Definitions
9	Financial Highlights
10	Management Discussion and Analysis
21	Other Information
32	Report on Review of Interim Financial Information
33	Interim Condensed Consolidated Income Statement
34	Interim Condensed Consolidated Statement of Comprehensive Loss
35	Interim Condensed Consolidated Balance Sheet
37	Interim Condensed Consolidated Statement of Changes in Equity
38	Interim Condensed Consolidated Statement of Cash Flows
39	Notes to the Condensed Consolidated Interim Financial Information



CORPORATION INFORMATION

BOARD OF DIRECTORS

Executive Directors

Mr. ZHAO Lu (*Chairman of the Board*)
Mr. MA Dong
Mr. ZHANG Hongwei
Mr. LU Yiming
Mr. HUANG Yufei
Ms. NI Xiaomei

Independent Non-Executive Directors

Dr. JIANG Xiao
Dr. LI Zhiguo
Mr. FUNG Che Wai Anthony

AUDIT COMMITTEE

Mr. FUNG Che Wai Anthony (*Chairman*)
Dr. JIANG Xiao
Dr. LI Zhiguo

REMUNERATION AND APPRAISAL COMMITTEE

Dr. LI Zhiguo (*Chairman*)
Mr. ZHAO Lu
Mr. FUNG Che Wai Anthony

NOMINATION COMMITTEE

Mr. ZHAO Lu (*Chairman*)
Dr. JIANG Xiao
Dr. LI Zhiguo
Ms. NI Xiaomei (*appointed on March 24, 2025*)
Mr. FUNG Che Wai Anthony (*appointed on March 24, 2025*)

SUPERVISORY COMMITTEE

Ms. DONG Xiaohan (*Chairlady*)
Mr. WEN Gang
Mr. CAI Xin

AUDITORS

PricewaterhouseCoopers
*Certificated Public Accountants and
Registered Public Interest Entity Auditor*
22/F Prince's Building Central
Hong Kong SAR, China

JOINT COMPANY SECRETARIES

Ms. NI Xiaomei
Mr. POON Ping Yeung

AUTHORISED REPRESENTATIVES

Ms. NI Xiaomei
Mr. POON Ping Yeung

REGISTERED OFFICE AND HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN CHINA

3/F, Building 9
Smart Industry Innovation Park
36 Changsheng South Road, Jiaxing
Zhejiang
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

19/F, Golden Centre
188 Des Voeux Road Central
Hong Kong

H SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17th Floor
Hopewell Centre
183 Queen's Road East
Wan Chai
Hong Kong

CORPORATION INFORMATION

PRINCIPAL BANKERS

**China Minsheng Banking Corp., Ltd.,
Jiaxing Sub-branch**
1818 Zuili Road
Nanhu District, Jiaxing
Zhejiang
PRC

**Bank of Hangzhou Co., Ltd.,
Jiaxing Sub-branch**
1/F, Yihong Building
1029 Chengnan Road
Nanhu District, Jiaxing
Zhejiang
PRC

LEGAL ADVISER

As to Hong Kong Laws
O'Melveny & Myers
31/F, AIA Central
1 Connaught Road Central
Hong Kong

As to PRC Laws
Jingtian & Gongcheng
34/F, Tower 3, China Central Place
77 Jianguo Road
Chaoyang District
Beijing
PRC

COMPLIANCE ADVISER

Anglo Chinese Corporate Finance, Limited
Room 4001, 40th Floor
Two Exchange Square
8 Connaught Place
Central
Hong Kong

STOCK CODE

2576

COMPANY WEBSITE

www.taimei.com

DEFINITIONS

In this interim report, unless the context otherwise requires, the following expressions shall have the following meanings.

"affiliate(s)"	with respect to any specified person, any other person, directly or indirectly, controlling or controlled by or under direct or indirect common control with such specified person
"Articles of Association"	the articles of association of the Company currently in force
"associate(s)"	has the meaning ascribed thereto under the Listing Rules
"Audit Committee"	the audit committee of the Board
"Board" or "Board of Directors"	the board of Directors
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"China" or "PRC"	the People's Republic of China excluding, for the purposes of this interim report Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan
"Company" or "our Company" or "Taimei Medical Technology"	Zhejiang Taimei Medical Technology Co., Ltd. (浙江太美醫療科技股份有限公司), a joint stock company with limited liability incorporated in the PRC, the predecessor of which was Jiaying Taimei Medical Technology Co., Ltd. (嘉興太美醫療科技有限公司), a limited liability company established in the PRC on June 6, 2013, and if the context requires, includes its predecessor
"CRO"	a contract research organization, which provides professional services to pharmaceutical companies and research institutions during the drug development process through contractual agreements
"Director(s)"	the director(s) of our Company
"Domestic Share(s)"	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for in Renminbi
"Global Offering"	has the meaning ascribed thereto in the Prospectus
"Group", "our Group", "our", "we" or "us"	the Company and its subsidiaries, or any one of them as the context may require or, where the context refers to any time prior to its incorporation, the business which its predecessors or the predecessors of its present subsidiaries, or any one of them as the context may require, were or was engaged in and which were subsequently assumed by it

DEFINITIONS

"H Share(s)"	overseas listed foreign invested ordinary share(s) in the ordinary share capital of our Company, with a nominal value of RMB1.00 each, which are listed on the Stock Exchange
"HIPAA"	The Health Insurance Portability and Accountability Act (HIPAA), a federal law in the United States, aims to protect patient medical information privacy and security. It requires healthcare providers and insurance companies to follow strict security and confidentiality protocols when handling patient data, including data encryption, access controls, and patient authorization. Applicable to all medical institutions within U.S. territory that handle healthcare data, HIPAA serves as the cornerstone of data protection in the healthcare industry
"HKD" or "HK\$"	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"ICH-GCP"	The Good Clinical Practice (GCP), established by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), represents a globally recognized framework for clinical trial ethics and scientific quality. This guideline ensures the reliability and integrity of clinical trial data while safeguarding participants' rights, safety, and well-being
"iCTA"	Document management agent, through AI to achieve intelligent classification, quality control and naming of test documents, significantly reduce compliance risks
"iDM"	Data management agent, through AI-driven automation technology, transforms complex solutions into compliant and high-quality data management workflow, intelligent data cleaning capability, greatly reduces DM workload, improve data quality
"IFRS"	International Financial Reporting Standards
"iPV"	The pharmacovigilance agent, through AI, can automate the processing of individual safety reports (ICSR), support intelligent translation in Chinese and English, and submit to multinational regulators
"IRC"	an independent reading center, which provides unbiased reviewing and analysis of clinical trial imaging data for accuracy and consistency
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange (as amended, supplemented or otherwise modified from time to time)
"Main Board"	the stock market (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the GEM of the Stock Exchange

DEFINITIONS

"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules
"Nomination Committee"	the nomination committee of our Board
"PDPA"	The Personal Data Protection Act (PDPA), implemented in Singapore and other jurisdictions, regulates the collection, use, and disclosure of personal data. It mandates that businesses obtain explicit user consent before processing personal information and must implement measures to ensure data security. While specific provisions of PDPA may vary slightly across countries, their core objective remains the same: protecting individual privacy
"Prospectus"	the prospectus issued by the Company and published on the websites of the Company and the Stock Exchange on September 27, 2024
"R&D"	research and development
"Remuneration and Appraisal Committee"	the remuneration and appraisal committee of our Board
"Reporting Period"	for the six months ended June 30, 2025
"RMB" or "Renminbi"	Renminbi, the lawful currency of the PRC
"Ruansu Enterprise Management"	Xinyu Ruansu Enterprise Management Partnership (Limited Partnership) (新余軟素企業管理合夥企業(有限合夥)) (formerly known as Shanghai Ruansu Enterprise Management Partnership (Limited Partnership) (上海軟素企業管理合夥企業(有限合夥))), a limited partnership established under the laws of the PRC on August 26, 2019, one of the Employee Shareholding Platforms and one of our Controlling Shareholders
"SaaS"	software-as-a-service
"Shanghai Kunrui"	Shanghai Kunrui Enterprise Management Partnership (Limited Partnership) (上海昆銳企業管理合夥企業(有限合夥)) (formerly known as Shanghai Kunrui Investment Management Partnership (Limited Partnership) (上海昆銳投資管理合夥企業(有限合夥))), a limited partnership established under the laws of the PRC on December 17, 2015, one of the Employee Shareholding Platforms and one of our Controlling Shareholders
"Shanghai Xiaoju"	Shanghai Xiaoju Enterprise Management Partnership (Limited Partnership) (上海小橘企業管理合夥企業(有限合夥)) (formerly known as Shanghai Xiaoju Investment Management Partnership (Limited Partnership) (上海小橘投資管理合夥企業(有限合夥))), a limited partnership established under the laws of the PRC on December 17, 2015, one of the Employee Shareholding Platforms and one of our Controlling Shareholders

DEFINITIONS

"Share(s)"	ordinary share(s) in the capital of our Company with a nominal value of RMB1.00 each, comprising Domestic Shares and H Shares
"Shareholder(s)"	holder(s) of the Share(s)
"SMO"	a site management organization, which is a commercial entity that assists clinical trial sites in conducting specific operational tasks for clinical trials
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed thereto under the Listing Rules
"Supervisor(s)"	the supervisor(s) of the Company
"U.S. dollars" or "USD" or "US\$"	United States dollars, the lawful currency of the United States
"United States"	the United States of America
"Xinyu Haolin"	Xinyu Haolin Enterprise Management Partnership (Limited Partnership) (新余浩霖企業管理合夥企業(有限合夥)) (formerly known as Jiaying Haolin Enterprise Management Partnership (Limited Partnership) (嘉興浩霖企業管理合夥企業(有限合夥))), a limited partnership established under the laws of the PRC on March 16, 2018, one of the Employee Shareholding Platforms and one of our Controlling Shareholders
"Xinyu Nuoming"	Xinyu Taimei Nuoming Enterprise Management Partnership (Limited Partnership) (新余太美諾銘企業管理合夥企業(有限合夥)), a limited partnership established under the laws of the PRC on March 11, 2020, one of the Employee Shareholding Platforms and one of our Controlling Shareholders
"Xinyu Qiwushi"	Xinyu Qiwushi Medical Technology Partnership (Limited Partnership) (新余七武士醫療科技合夥企業(有限合夥)) (formerly known as Jiaying Qiwushi Medical Technology Partnership (Limited Partnership) (嘉興七武士醫療科技合夥企業(有限合夥))), a limited partnership established under the laws of the PRC on December 20, 2018, one of the Employee Shareholding Platforms and one of our Controlling Shareholders
"Xinyu Shenkong"	Xinyu Shenkong Enterprise Management Partnership (Limited Partnership) (新余深空企業管理合夥企業(有限合夥)), a limited partnership established under the laws of the PRC on August 19, 2019 and one of our Controlling Shareholders
"Xinyu Xingmeng"	Xinyu Taimei Xingmeng Enterprise Management Partnership (Limited Partnership) (新余太美星盟企業管理合夥企業(有限合夥)), a limited partnership established under the laws of the PRC on September 16, 2021, one of the Employee Shareholding Platforms and one of our Controlling Shareholders

DEFINITIONS

“Zhoushan Yijin”	Zhoushan Yijin Investment Management Partnership (Limited Partnership) (舟山憶瑾投資管理合夥企業(有限合夥)) (formerly known as Jiaxing Yijin Enterprise Management Consulting Partnership (Limited Partnership) (嘉興憶瑾企業管理諮詢合夥企業(有限合夥))), a limited partnership established under the laws of the PRC on November 7, 2016 and one of our Controlling Shareholders
“%”	percent

Note: The English translation of Chinese names of entities included in this interim report is prepared for identification purpose only.

FINANCIAL HIGHLIGHTS

	Six months Ended June 30,		2024		Year-on-year change (%)
	2025	% of		% of	
	<i>RMB'000</i>	<i>Revenue</i>	<i>RMB'000</i>	<i>Revenue</i>	
Revenue	244,221	100.0	272,784	100.0	-10.5
Gross profit	100,188	41.0	110,944	40.7	-9.7
Operating loss	(48,710)	-19.9	(191,995)	-70.4	-74.6
Loss for the period	(29,309)	-12.0	(175,317)	-64.3	-83.3
Adjusted net loss (non-IFRS measure) ⁽¹⁾	(28,696)	-11.8	(49,253)	-18.1	-41.7

	As at	As at	Year-on-year change
	June 30, 2025	December 31, 2024	
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
Total assets	1,518,520	1,583,197	(64,677)
Total liabilities	302,104	348,624	(46,520)
Equity attributable to equity holders of the Company	1,146,000	1,157,810	(11,810)
Non-controlling interests	70,416	76,763	(6,347)
Cash and cash equivalents	253,013	319,297	(66,284)

⁽¹⁾ See the section headed "Adjusted net loss (non-IFRS measure)" for more information about the non-IFRS Accounting Standards measures.

MANAGEMENT DISCUSSION AND ANALYSIS

(I) BUSINESS OVERVIEW


Our revenue decreased by 10.5% from RMB272.8 million in the six months ended June 30, 2024 to RMB244.2 million in the six months ended June 30, 2025, mainly due to the decline of revenue from digital services.

Our gross profit decreased by 9.7% from RMB110.9 million in the six months ended June 30, 2024 to RMB100.2 million in the six months ended June 30, 2025, mainly due to the decline in revenue. Our gross profit margin increased slightly from 40.7% in the six months ended June 30, 2024 to 41.0% in the six months ended June 30, 2025.

We recorded a loss for the six months ended June 30, 2025 of RMB29.3 million, compared to a loss for the six months ended June 30, 2024 of RMB175.3 million. After excluding listing expenses related to the Company's Global Offering and share-based payments, the adjusted net loss was RMB28.7 million, down 41.7% year on year.

Our Industry Solutions

Our solutions for the pharmaceutical and medical device industry consist of cloud-based software, including SaaS products, customized products, and digital services. Our SaaS products and digital services are primarily offered through digital collaboration platforms, including "Trials R&D Collaboration Platform" and "PharmaOS Pharmaceutical Digital Marketing Platform", and are partially intelligentized by the Literary Intelligence. Our limited customized products are mainly hosted on a private cloud, in-house infrastructure, rather than through "Trials R&D Collaboration Platform" or "PharmaOS Pharmaceutical Digital Marketing Platform". The following diagram illustrates our main products and services:



MANAGEMENT DISCUSSION AND ANALYSIS

Digital Collaboration Platforms

Our industry solutions are based on the digital collaboration platform for pharmaceutical and medical device research and development, the “Trials R&D Collaboration Platform”, and the digital collaboration platform for pharmaceutical and medical device commercialization, the “PharmaOS Pharmaceutical Digital Marketing Platform”. Staff from pharmaceutical companies, hospitals, CROs/SMOs and other relevant parties can easily manage and use our cloud-based software products and digital services through a unified landing page on the platforms, access the latest information and collaborate online. The underlying technology of our platforms breaks the boundaries between organizations and supports data interoperability among different software products and digital services, enabling efficient R&D and commercialization of innovative drugs and medical devices. The “Trials R&D Collaboration Platform”, with its new client-side interface and conversation-based interaction, will deliver a more intuitive user experience and facilitate rapid collaboration, further breaking down artificial barriers between different software and services, orienting itself towards users’ needs for external collaboration and process management. The “PharmaOS Pharmaceutical Digital Marketing Platform” is expected to achieve easier, more efficient, direct and compliant interaction between pharmaceutical companies and physicians by integrating online channels.

Cloud-based Software

Based on our digital collaboration platforms, we have built a series of software for different types of organizations and roles and covering critical use cases in pharmaceutical and medical device R&D and commercialization. For instance, our software facilitates the planning, tracking and monitoring of site and trial-related activities, and streamlines the management and filing of clinical research documents. Our software can also be used for patient recruitment, patient follow-up, data collection and analysis, as well as sales relationship management, to address the challenges faced by industry participants and improve workflow efficiency. The cloud-based software that we offer is hosted by a cloud service provider and offered to customers via cloud service, instead of running locally on our customers’ devices with no network connection. We offer our SaaS products through the “Trials R&D Collaboration Platform” or the “PharmaOS Pharmaceutical Digital Marketing Platform”, which leverage public cloud service to deliver our SaaS products via the internet across organizations. We also deliver our customized products primarily via private cloud service, which resides on a single organization’s in-house infrastructure instead of utilizing the “Trials R&D Collaboration Platform” or the “PharmaOS Pharmaceutical Digital Marketing Platform”.

MANAGEMENT DISCUSSION AND ANALYSIS

For our cloud-based software, we generally recognize the revenue over the contract term since our delivery of products and in accordance with our customers' consumption of products or at a point of time when such product is delivered to and accepted by our customers. During the Reporting Period, the majority of our revenue from cloud-based software was derived from SaaS products.

In the first half of 2025, 38.7% of our revenue was generated from the sales of our cloud-based software. For our SaaS products, generally, we recognize the revenue over the contract term since our delivery of products and in accordance with our customers' consumption of products.

Digital Services

Based on our understanding of the industry and to better cater to the demands of different types of customers, we also provide our customers with a range of digital services, primarily assisting customers with independent medical image assessment, achieving efficient SMO resource distribution and execution, offering pharmacovigilance services and other services to support our customers' R&D and commercialization activities. These digital services are based on our digital collaboration platforms and linked with SaaS products to enable online operation, monitoring and management for improved efficiency and quality. By offering digital services, we further accumulate industry knowledge and insights, which helps enhance our capability to optimize our platforms and software products.

By choosing our digital services, our customers can leverage our service personnel who are well-versed in our software to fulfill their needs with consistent quality and no additional staff overhead. Our IRC service primarily helps pharmaceutical and medical device companies conduct independent medical image assessment. In the meantime, our digital clinical research services include digital SMO business management, which offers integrated service related to training, management, and supervision of SMO service delivery, pharmacovigilance service, and also digital clinical trial services, which enable digitally decomposing and streamlining operations of clinical research for quality, transparency, and efficiency, and realize real-time risk alerts and achieves digital project management. These digital services typically integrate the capabilities of our corresponding cloud-based software and platforms, and therefore our customers would typically also be paid users of the corresponding cloud-based software, though our customers can also use some of our digital services without becoming paid users of our cloud-based software. For example, per customer request, the Company occasionally delivered pharmacovigilance service without leveraging our software. For our digital services, we recognize revenue over contract term since our delivery of services and in accordance with the progress of our service obligation performance.

In the first half of 2025, 61.2% of our revenue was generated from the provision of digital services.

MANAGEMENT DISCUSSION AND ANALYSIS

(II) BUSINESS OUTLOOK AND PROSPECTS

- **Continue to enhance AI research & development to promote future growth**

We will continue to explore advanced technologies to enhance our core capabilities and maintain our position in the industry. In the first half of 2025, our officially released “Clinical Research Digital Intelligence Evolution Blueprint” launched a value-oriented AlaaS (AI as a service) collaboration model through the deep integration of large AI models and SaaS platforms, covering the entire drug lifecycle of intelligence services, which would enable a leapfrog upgrade from “digital tools” to “value creation” within the pharmaceutical industry. Our initially pioneered “Digital Employee” system, embeds AI agents throughout the clinical research process, achieving a breakthrough from “productivity tools” to “productive force”. Relevant “Digital Employees” include:

- ✓ iDM Data Management Intelligent Agent: automatically generates CRFs (Case Report Forms) and validation plans based on clinical trial protocols, improving database construction efficiency by 80% and reducing error rates by 50%.
- ✓ iCTA Document Management Intelligent Agent: realizes intelligent classification, quality control, and naming of trial documents through AI, reducing attribute filling time by 70%, and significantly lowering compliance risks.
- ✓ iPV Pharmacovigilance Intelligent Agent: automates the processing of individual case safety reports (ICSRs), and supports intelligent translation between Chinese and English, and cross-border regulatory submissions, improving efficiency by 300%.
- ✓ iSeeK Center Screening Intelligent Agent: utilizes AI to analyze historical enrollment data and cost structures, compressing the research center evaluation cycle from 7 days to 16 hours, and accurately recommending high-potential institutions.
- ✓ iMAP Intelligent Medical Monitor: real-time analyzes the treatment efficacy and adverse event data, and automatically generates visual reports, helping researchers identify risks swiftly.

We will continue to increase our AI R&D investment to enhance our overall technological strength and product competitiveness. Concurrently, we will promote the industrialization of our technological achievements and continue to improve the conversion rate of R&D investment to enhance our profitability. Furthermore, we plan to attract outstanding technical talents from the medical, pharmaceutical, and digital industries. We will continue to invest more resources to establish a comprehensive talent development system, fostering an innovative culture and nurturing talent within the Company.

MANAGEMENT DISCUSSION AND ANALYSIS

- **Promote the implementation of the AlaaS business model to realize more value conversion**

We will take the “Digital Employee” system as our core platform, translating AlaaS from a concept into measurable cash flow through repeat purchase activities. Multiple intelligent agents, such as iDM, iCTA, and iPV, are embedded into the Trials/PharmaOS platforms, with billing based on a dual dimension of “task volume + effect”. Supported by our compliant delivery centers in China, the United States, and Singapore, we will gradually achieve a closed commercial loop from “digital tools” to “value sharing”.

Drawing on our expertise in data security and compliance, we will adopt advanced technologies, such as multi-cloud deployment and containerization technology, as well as cloud computing security measures, to improve our product and service offerings. These initiatives will adapt our product mix to the evolving IT infrastructure of global pharmaceutical and medical device companies, enabling us to provide secure and compliant solutions to meet developing industry needs.

- **Foster global collaboration through international expansion**

Global innovative drugs have become a significant area for the realization of technological progress. During the past 15 years since 2010, China’s innovative drug industry chain has achieved a substantial leap in overall R&D and production levels, with the influence of Chinese innovative drugs continuing to increase in the international market. Furthermore, pharmaceutical R&D services have become a crucial engine driving the development of the entire industry. As an “AI-driven technology company empowering the life sciences industry”, we will grow together with Chinese innovative pharmaceutical companies and make our strides in the international market. Our Company has established three data and delivery centers across the globe, including China, the United States, and Singapore. With our excellent international presence, our products and services have obtained numerous domestic and overseas authoritative certifications and validations, including HIPAA, PDPA, and ICH-GCP. The AI-driven global intelligent clinical solutions we provide will significantly contribute to the development of the life sciences industry at home and abroad. Through these efforts, we aim to address our customers’ demands for high-quality and efficient multi-regional clinical trials.

To capitalize on the global momentum in pharmaceutical and medical device digitalization, we plan to develop international commercialization strategies tailored to overseas markets. Leveraging our early-mover advantage and technological capabilities, we will facilitate the construction of a global interconnected platform and offer advanced digital intelligence solutions to international pharmaceutical companies, thereby fostering global pharmaceutical and medical device innovation and empowering the development of the life sciences industry.

MANAGEMENT DISCUSSION AND ANALYSIS

(III) FINANCIAL REVIEW

Revenues

	Six Months Ended June 30,		2024		Year-on-year
	2025	% of	2024	% of	change
	RMB'000	Revenue	RMB'000	Revenue	(%)
Cloud-based Software					
– SaaS products	82,425	33.8	81,564	29.9	1.1
– Customized products	12,171	5.0	15,993	5.9	-23.9
Subtotal	94,596	38.7	97,557	35.8	-3.0
Digital Services	149,371	61.2	175,227	64.2	-14.8
Others	254	0.1	–	–	N/A
Total	244,221	100.0	272,784	100.0	-10.5

We primarily derive our revenue from (i) the sales of our cloud-based software, including SaaS products and customized products, as well as relevant technical support; and (ii) provision of digital services, primarily including digital clinical research services and IRC services.

Our revenue decreased by 10.5% from RMB272.8 million in the six months ended June 30, 2024 to RMB244.2 million in the six months ended June 30, 2025, mainly due to the decline of revenue from digital services.

Cloud-based Software: Our revenue from sales of cloud-based software declined 3.0% from RMB97.6 million in the six months ended June 30, 2024 to RMB94.6 million in the six months ended June 30, 2025, which was primarily attributable to the decrease in sales of the customized products from RMB16.0 million in the six months ended June 30, 2024 to RMB12.2 million in the six months ended June 30, 2025. Such decline in customized-product revenue was primarily due to intensifying market competition and the Group's increased focus on core customers.

Digital services: Our revenue from sales of digital services decreased by 14.8% from RMB175.2 million in the six months ended June 30, 2024 to RMB149.4 million in the six months ended June 30, 2025, mainly due to the impact of a challenging external environment and the Group's strategic pivot toward key accounts.

MANAGEMENT DISCUSSION AND ANALYSIS

Cost of sales

Our cost of sales decreased by 11.0% from RMB161.8 million in the six months ended June 30, 2024 to RMB144.0 million in the six months ended June 30, 2025, primarily attributable to the improvement of labor efficiency and the decline in revenue.

Gross profit and gross margin

Our gross profit decreased by 9.7% from RMB110.9 million in the six months ended June 30, 2024 to RMB100.2 million in the six months ended June 30, 2025, mainly due to the decline in revenue. Our gross profit margin increased slightly from 40.7% in the six months ended June 30, 2024 to 41.0% in the six months ended June 30, 2025.

Selling expenses

Our selling expenses decreased by 26.6% from RMB51.2 million in the six months ended June 30, 2024 to RMB37.6 million in the six months ended June 30, 2025, primarily due to a reduction of RMB8.6 million in staff costs and a decrease of RMB3.1 million in our share-based payments.

Administrative expenses

Our administrative expenses decreased by 73.4% from RMB217.2 million in the six months ended June 30, 2024 to RMB57.7 million in the six months ended June 30, 2025, primarily due to (i) a significant decrease of RMB121.3 million in our share-based payments, which mainly related to the acquisition of certain indirect equity interests in a subsidiary of the Company, Taimei Intelligence Pharmaceutical (Shanghai) R&D Co., Ltd. (“太美智研醫藥研發(上海)有限公司”) by certain Shareholders in January 2024; and (ii) a decrease of RMB30.3 million in our staff costs resulting from improved labor efficiency.

Research and development expenses

Our research and development expenses decreased by 26.0% from RMB50.9 million in the six months ended June 30, 2024 to RMB37.7 million in the six months ended June 30, 2025, primarily attributable to our decrease in staff costs of RMB10.2 million.

Net impairment losses on financial and contract assets

We recorded net impairment losses on financial and contract assets of RMB1.3 million in the six months ended June 30, 2024 and RMB5.5 million in the six months ended June 30, 2025. Such change was primarily driven by an increase in the credit risk of a few customers.

Other income

Our other income decreased from RMB9.8 million in the six months ended June 30, 2024 to RMB2.4 million in the six months ended June 30, 2025, primarily due to the decrease of RMB6.8 million in government grants.

MANAGEMENT DISCUSSION AND ANALYSIS

Other (losses)/gains – net

We recorded net other losses of RMB12.9 million in the six months ended June 30, 2025, including a net foreign exchange losses of RMB16.1 million, and we recorded net gains of RMB7.8 million in the six months ended June 30, 2024, which included a net foreign exchange gains of RMB5.3 million. The swing was primarily driven by significant volatility in the US\$ to RMB exchange rate.

Finance income – net

Our net finance income increased from RMB16.7 million in the six months ended June 30, 2024 to RMB19.4 million in the six months ended June 30, 2025 primarily due to an increase of RMB2.8 million in interest income.

Loss for the period

As a result of the above, our loss for the period decreased by 83.3% from RMB175.3 million for the six months ended June 30, 2024 to RMB29.3 million for the six months ended June 30, 2025.

Adjusted net loss (non-IFRS measure)

To supplement our consolidated financial statements, which are presented in accordance with IFRS, we also use adjusted net loss as an additional non-IFRS measure, which is not required by, or presented in accordance with, IFRS.

We define adjusted net loss (a non-IFRS measure) as the loss for the period adjusted by adding back share-based payments and listing expenses. We believe the presentation of this non-IFRS measure provides useful information to investors and management in facilitating a comparison of our operating performance from year to year by eliminating potential impacts of these items. However, our presentation of adjusted net loss may not be comparable to similarly titled measures presented by other companies. The use of this non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for, an analysis of our results of operations or financial condition as reported under IFRS.

The tables below set forth the reconciliation of our non-IFRS measure presented in accordance with IFRS for the six months ended June 30, 2025 indicated:

	Six Months Ended June 30,	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Loss for the period	(29,309)	(175,317)
Adjustment:		
Share-based payments	613	115,078
– Share-based payments to employees	613	22,242
– Share-based compensation to certain shareholders	–	92,836
Listing expenses in connection with the Global Offering	–	10,986
Adjusted net loss for the period (a non-IFRS measure)	(28,696)	(49,253)

MANAGEMENT DISCUSSION AND ANALYSIS

Liquidity and capital resource

Our principal use of cash in the six months ended June 30, 2025 was for working capital purposes. Our main source of liquidity has been generated from proceeds from our business operations, the net proceeds from the Global Offering, and bank borrowings. We do not anticipate any changes to the availability of financing to fund our operations in the future.

As at June 30, 2025, the Group had net current assets of RMB1,170.8 million (December 31, 2024: RMB1,184.5 million) of which cash and cash equivalents, short-term bank deposits, short-term treasury investments, and restricted cash were RMB253.0 million, RMB736.1 million, RMB160.1 million and RMB0.1 million (December 31, 2024: RMB319.3 million, RMB599.9 million, RMB159.4 million and RMB5.1 million), respectively. Total bank borrowing was nil (December 31, 2024: RMB10.0 million). The Group's cash and cash equivalents are mainly denominated in RMB.

As at June 30, 2025, the Group's current ratio⁽¹⁾ was 5.66 (December 31, 2024: 5.05) and gearing ratio⁽²⁾ was 19.9% (December 31, 2024: 22.0%). The Group has sufficient cash to meet its working capital requirements. This strong cash position enables the Group to explore potential business development opportunities to expand in China and overseas.

Notes:

- (1) Current ratio equals current assets divided by current liabilities as at the same date.
- (2) Gearing ratio equals total liabilities divided by total assets and multiplied by 100% as at the same date.

Pledge of assets

As at June 30, 2025, the Group had no pledge of assets.

Exchange rate fluctuation risk

During the six months ended June 30, 2025, the Group mainly operated in China with most of the transactions settled in Renminbi. The functional currency of the Company and the subsidiaries that operate in the PRC, and the subsidiaries operate in the United States and Singapore are Renminbi, U.S. dollar and Singapore dollar, respectively. For the six months ended June 30, 2025, we had currency translation gains of RMB10.5 million (for the six months ended June 30, 2024: losses of RMB2.1 million) and net foreign exchange losses of RMB16.1 million (for the six months ended June 30, 2024: gains of RMB5.3 million).

We did not hedge against any fluctuation in foreign currency during the six months ended June 30, 2025.

MANAGEMENT DISCUSSION AND ANALYSIS

Future Plan for Material Investment and Capital Asset

The Group does not have any other plans for material investments and capital assets for the Reporting Period and up to the date of this report.

Significant Investments, Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures during the Reporting Period

The Group did not hold or make any significant investments, material acquisitions or disposals of subsidiaries, associates and joint ventures during the Reporting Period.

Contingent liabilities

As at June 30, 2025, we did not have any material contingent liabilities.

Capital commitment

As at June 30, 2025, we did not have any material capital commitments.

Off-balance sheet commitments and arrangements

As at June 30, 2025, we had not entered into any off-balance sheet transactions.

Employees and remuneration

As at June 30, 2025, we had 656 full-time employees, of whom 648 were based in China, 4 were based in the United States and 4 were based in Singapore. The table below sets forth a breakdown of our full-time employees by function as at June 30, 2025:

Function	Numbers of Employees	% of Total
R&D	127	19.4
Sales and Marketing	85	13.0
Professional and Technical Personnel	359	54.7
Administrative	85	13.0
Total	656	100.0

Our total remuneration cost for the six months ended June 30, 2025, was RMB152.1 million (for the six months ended June 30, 2024: RMB209.6 million).

MANAGEMENT DISCUSSION AND ANALYSIS

Use of proceeds from the Global Offering

The H Shares were first listed on the Main Board of the Stock Exchange on October 8, 2024. After deducting underwriting fees, commissions and other related listing expenses, the total net proceeds of the Global Offering amounted to approximately HK\$259.5 million (the “**Net Proceeds**”). The Net Proceeds have been allocated and utilized in accordance with the intended purposes and proportions as set out in the Prospectus, and there is no change in the intended use of the Net Proceeds as disclosed in the Prospectus.

The following table sets out the status of the use of the Net Proceeds and a summary of their utilization as at June 30, 2025 together with the expected timeline of use:

Intended use of Net Proceeds		Allocation of Net Proceeds	Approximate percentage of total Net Proceeds	Balance of Net Proceeds unutilized as at December 31, 2024	Amount of Net Proceeds utilized up to June 30, 2025	Balance of Net Proceeds unutilized as at June 30, 2025	Intended timetable for use of the unutilized Net Proceeds ^(note)
(i)	To improve and upgrade our TrialOS Platform and PharmaOS Platform and their respective cloud-based software and digital services	HK\$90.8 million	35%	HK\$89.4 million	HK\$9.2 million	HK\$81.6 million	Before December 31, 2029
(ii)	To improve our core technology and R&D capabilities	HK\$77.9 million	30%	HK\$75.8 million	HK\$5.7 million	HK\$72.2 million	Before December 31, 2029
(iii)	To strengthen our sales and marketing capabilities	HK\$26.0 million	10%	HK\$26.0 million	HK\$0.7 million	HK\$25.3 million	Before December 31, 2029
(iv)	To selectively pursue strategic investments and acquisitions	HK\$38.9 million	15%	HK\$38.9 million	HK\$ -	HK\$38.9 million	Before December 31, 2029
(v)	For our working capital and general corporate purposes	HK\$25.9 million	10%	HK\$24.1 million	HK\$3.1 million	HK\$22.9 million	Before December 31, 2029
Total		HK\$259.5 million	100%	HK\$254.2 million	HK\$18.7 million	HK\$240.8 million	

Note: The expected timeline to use the remaining Net Proceeds is prepared based on the best estimate made by the Group, which is subject to change based on future developments and events which may be outside of the Group's control.

OTHER INFORMATION

INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the Reporting Period (six months ended June 30, 2024: Nil).

CORPORATE GOVERNANCE

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability. The Company has adopted the principles and code provisions set out in the CG Code as set out in Part 2 of Appendix C1 to the Listing Rules as its own code to govern its corporate governance practices. During the Reporting Period, the Company has complied with all applicable code provisions of the CG Code except for the deviations as explained below. The Company will continue to review and monitor its corporate governance practices to ensure compliance with the CG Code.

Under paragraph F.1.1 of part 2 of the CG Code, an issuer should have a policy on payment of dividends. The Company currently expects to retain all future earnings for use in operation and expansion of our business, and currently does not have any dividend policy to declare or pay any dividends in the foreseeable future. The declaration and payment of any dividends in the future will be determined by the Board and subject to the Articles of Association and the Company Law of the PRC (《中華人民共和國公司法》), and will depend on a number of factors, including the Group's financial performance and business operation, capital requirements and contractual restrictions. No dividend shall be declared or payable except out of profits and reserves lawfully available for distribution. As confirmed by the legal adviser to the Company as to PRC laws, according to the PRC laws, any future net profit that the Company makes will have to be first applied to make up for its historically accumulated losses, after which the Company will be obliged to allocate 10% of its net profit to its statutory common reserve fund until such fund has reached more than 50% of its registered capital. The Company will therefore only be able to declare dividends after (i) all its historically accumulated losses have been made up for; and (ii) the Company has allocated sufficient net profit to its statutory common reserve fund as described above. The Board will review the Company's status periodically and consider adopting a dividend policy if and when appropriate.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as set out in Appendix C3 to the Listing Rules as its own code of conduct regarding dealings by Directors, Supervisors, and the Group's senior management who, because of his/her office or employment, is likely to possess inside information in relation to the Company's securities.

Upon specific enquiries, all Directors and Supervisors have confirmed that they have complied with the Model Code throughout the Reporting Period. In addition, the Company is not aware of any non-compliance of the Model Code by the senior management of the Group throughout the Reporting Period.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

During the six months ended June 30, 2025, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities or sold any treasury Shares (as defined under the Listing Rules). As at June 30, 2025, the Company did not hold any treasury Shares (as defined under the Listing Rules).

OTHER INFORMATION

AUDIT COMMITTEE

The Audit Committee has been established with written terms of reference in compliance with the Listing Rules and the CG code. The Audit Committee comprises three members, including three independent non-executive Directors, namely Mr. FUNG Che Wai Anthony, Dr. JIANG Xiao and Dr. LI Zhiguo. Mr. FUNG Che Wai Anthony, who holds the appropriate professional qualifications as required under Rules 3.10(2) of the Listing Rules, is the chairman of the Audit Committee.

The Audit Committee has reviewed and considered that the interim financial results for the six months ended June 30, 2025 are in compliance with the relevant accounting standards, rules and regulations and appropriate disclosures have been duly made. There is no disagreement by the Audit Committee with respect to the accounting treatment adopted by the Company.

EVENTS AFTER THE REPORTING PERIOD

Change of chief financial officer

The Company received a resignation letter from Mr. JIANG Chengwen (姜程文) to resign as the chief financial officer of the Company with effect from July 25, 2025, due to his other personal commitments. On July 25, 2025, the Board resolved to appoint Mr. WANG Wei (王為) as the chief financial officer of the Company with effect from the same date. For further details, please refer to the announcement of the Company dated July 25, 2025.

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at June 30, 2025, the interests and short positions of the Directors, Supervisors and chief executives of the Company in the Shares, underlying Shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which had been notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO), or which were recorded in the register required to be kept pursuant to section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

OTHER INFORMATION

Interests in Shares

Name of Director	Position	Nature of interest	Class of Shares	Number of Shares/ Underlying Shares held	Approximate percentage of shareholding in the class of Shares issued (%) ⁽¹⁾	Approximate percentage of shareholding in the total Shares issued (%) ⁽¹⁾
Mr. Zhao Lu ⁽²⁾	Chairman of our Board and executive Director	Beneficial owner; Interests in controlled corporations	Domestic Shares	178,203,028	49.07	31.61
			H Shares	1,216,500	0.61	0.22
Mr. ZHANG Hongwei ⁽³⁾	Executive Director and president of digital marketing division	Interests in controlled corporations	Domestic Shares	20,312,190	5.59	3.60

Notes:

- As of June 30, 2025, there were 563,779,000 Shares in total, including 363,186,467 Domestic Shares and 200,592,533 H Shares.
- As of June 30, 2025, Mr. ZHAO Lu beneficially holds 93,042,388 Domestic Shares. Mr. Zhao is the executive partner of Shanghai Xiaoju, Shanghai Kunrui, Xinyu Haolin, Xinyu Qiwushi, Ruansu Enterprise Management, Xinyu Nuoming and Xinyu Xingmeng, and is responsible for their respective management. He also held approximately 74.94% partnership interest in Ruansu Enterprise Management. Further, Mr. Zhao is the general partner of Zhoushan Yijin and Xinyu Shengkong, and is responsible for their respective management. As such, under the SFO, Mr. Zhao is deemed to be interested in the 85,160,640 Domestic Shares and 1,216,500 H Shares held by Shanghai Xiaoju, Shanghai Kunrui, Xinyu Haolin, Xinyu Qiwushi, Ruansu Enterprise Management, Xinyu Nuoming, Xinyu Xingmeng, Zhoushan Yijin and Xinyu Shengkong.
- As of June 30, 2025, Mr. ZHANG Hongwei held approximately 39.42% in Shanghai Xiaoju as one of its limited partners. As such, under the SFO, Mr. ZHANG Hongwei is deemed to be interested in the 20,312,190 Domestic Shares held by Shanghai Xiaoju.
- All interests are long positions.

Save as disclosed above, as at June 30, 2025, none of the Directors, Supervisors or chief executives of the Company had or was deemed to have any interest or short position in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which was required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO), or which were required to be recorded in the register to be kept by the Company under Section 352 of the SFO, or which were required to be notified to the Company and the Stock Exchange pursuant to the Model Code.

OTHER INFORMATION

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at June 30, 2025, so far as the Directors are aware, the following persons (not being a Director, Supervisor or chief executives of the Company) had interests or short positions in the Shares or underlying Shares which fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO as recorded in the register required to be kept by the Company pursuant to section 336 of the SFO:

Interests in Shares

Name of Shareholder	Capacity/nature of interest	Number of Shares held	Approximate percentage of shareholding in the relevant proportion of Shares ⁽¹⁾ (%)	Approximate percentage of shareholding in the total issued share capital of our Company ⁽¹⁾ (%)
Tang Lili ⁽²⁾	Interests in controlled corporations; Interest of spouse	178,203,028 Domestic Shares	49.07	31.61
Shanghai Kunrui ⁽²⁾	Beneficial owner	19,344,866 Domestic Shares	5.33	3.43
Shanghai Xiaoju ⁽²⁾	Beneficial owner	20,312,190 Domestic Shares	5.59	3.60
Xinyu Shengkong ⁽²⁾	Beneficial owner	18,204,844 Domestic Shares	5.01	3.23
Oriental Power Holdings Limited ⁽³⁾⁽⁴⁾	Interests in controlled corporations	51,911,405 Domestic Shares	14.29	9.21
		12,977,851 H Shares	6.47	2.30
Tencent Holdings Limited ⁽³⁾⁽⁴⁾	Interests in controlled corporations	51,911,405 Domestic Shares	14.29	9.21
		12,977,851 H Shares	6.47	2.30
Tencent Technology (Shenzhen) Company Limited (騰訊科技(深圳)有限公司) ⁽³⁾⁽⁴⁾	Interests in controlled corporations	51,911,405 Domestic Shares	14.29	9.21
		12,977,851 H Shares	6.47	2.30
MA Huateng ⁽³⁾	Interests in controlled corporations	44,880,821 Domestic Shares	12.36	7.96
		11,220,205 H Shares	5.59	1.99
Linzi Tencent Investment Management Co., Ltd. (林芝騰訊投資管理有限公司) ⁽³⁾	Beneficial owner	44,880,821 Domestic Shares	12.36	7.96
		11,220,205 H Shares	5.59	1.99

OTHER INFORMATION

Name of Shareholder	Capacity/nature of interest	Number of Shares held	Approximate percentage of shareholding in the relevant proportion of Shares ⁽¹⁾ (%)	Approximate percentage of shareholding in the total issued share capital of our Company ⁽¹⁾ (%)
Shenzhen Tencent Industrial Investment Fund Co., Ltd. (深圳市騰訊產業投資基金有限公司) ⁽³⁾	Interests in controlled corporations	44,880,821 Domestic Shares 11,220,205 H Shares	12.36 5.59	7.96 1.99
Shenzhen Tencent Ruitou Enterprise Management Co., Ltd. (深圳市騰訊睿投企業管理有限公司) ⁽³⁾	Interests in controlled corporations	44,880,821 Domestic Shares 11,220,205 H Shares	12.36 5.59	7.96 1.99
Shenzhen Tencent Ruijian Investment Co., Ltd. (深圳市騰訊睿見投資有限公司) ⁽³⁾	Interests in controlled corporations	44,880,821 Domestic Shares 11,220,205 H Shares	12.36 5.59	7.96 1.99
Shenzhen Tenglv Enterprise Management Partnership (Limited Partnership) (深圳市藤綠企業管理合夥企業(有限合夥)) ⁽³⁾	Interests in controlled corporations	44,880,821 Domestic Shares 11,220,205 H Shares	12.36 5.59	7.96 1.99
Shenzhen Tengyuan Enterprise Management Partnership (Limited Partnership) (深圳市藤遠企業管理合夥企業(有限合夥)) ⁽³⁾	Interests in controlled corporations	44,880,821 Domestic Shares 11,220,205 H Shares	12.36 5.59	7.96 1.99
Shenzhen Tengqing Enterprise Management Co., Ltd. (深圳市藤青企業管理有限公司) ⁽³⁾	Interests in controlled corporations	44,880,821 Domestic Shares 11,220,205 H Shares	12.36 5.59	7.96 1.99
Jingwei Chuangteng (Hangzhou) Venture Capital Partnership (Limited Partnership) (經緯創騰(杭州)創業投資合夥企業(有限合夥)) ("Jingwei Chuangteng") ⁽⁵⁾	Beneficial owner	22,349,533 Domestic Shares 28,100,879 H Shares	6.15 14.01	3.96 4.98

OTHER INFORMATION

Name of Shareholder	Capacity/nature of interest	Number of Shares held	Approximate percentage of shareholding in the relevant proportion of Shares ⁽¹⁾ (%)	Approximate percentage of shareholding in the total issued share capital of our Company ⁽¹⁾ (%)
Hangzhou Jingwei Yuanchuang Investment Management Partnership (Limited Partnership) (杭州經緯遠創投資管理合夥企業(有限合夥)) (“Jingwei Yuanchuang”) ⁽⁵⁾	Interests in controlled corporations	22,349,533 Domestic Shares	6.15	3.96
		28,100,879 H Shares	14.01	4.98
Shanghai Jingwei Equity Investment Management Co., Ltd. (上海旌威股權投資管理有限公司) (“Shanghai Jingwei”) ⁽⁵⁾	Interests in controlled corporations	22,349,533 Domestic Shares	6.15	3.96
		28,100,879 H Shares	14.01	4.98
ZUO Lingye ⁽⁵⁾	Interests in controlled corporations	23,908,953 Domestic Shares	6.58	4.24
		30,061,593 H Shares	14.99	5.33
Suzhou Northern Lights Zhengyuan Venture Capital Partnership (Limited Partnership) (蘇州北極光正源創業投資合夥企業(有限合夥)) ⁽⁶⁾	Beneficial owner	10,139,955 H Shares	5.06	1.80
Suzhou Boyuan Venture Capital Management Partnership (Limited Partnership) (蘇州柏源創業投資管理合夥企業(有限合夥)) ⁽⁶⁾	Interests in controlled corporations	15,930,449 H Shares	7.94	2.83
Suzhou Songyuan Entrepreneurship Investment Management Co., Ltd. (蘇州松源創業投資管理有限公司) ⁽⁶⁾	Interests in controlled corporations	15,930,449 H Shares	7.94	2.83
ZHANG Pengpeng ⁽⁶⁾	Interests in controlled corporations	15,930,449 H Shares	7.94	2.83

OTHER INFORMATION

Name of Shareholder	Capacity/nature of interest	Number of Shares held	Approximate percentage of shareholding in the relevant proportion of Shares ⁽¹⁾ (%)	Approximate percentage of shareholding in the total issued share capital of our Company ⁽¹⁾ (%)
Shanghai Chenxi Venture Capital Center (Limited Partnership) (上海晨熹創業投資中心(有限合夥)) ("5Y Chenxi")	Beneficial owner	11,514,965 H Shares	5.74	2.04
Shanghai Yuanpan Enterprise Management Consulting Partnership (Limited Partnership) (上海源畔企業管理諮詢合夥企業(有限合夥))	Interests in controlled corporations	11,514,965 H Shares	5.74	2.04
XUE Qiong	Interests in controlled corporations	11,514,965 H Shares	5.74	2.04
CHEN Yihai	Interest of spouse	11,514,965 H Shares	5.74	2.04
Shanghai Xingshang Enterprise Management Consulting Co., Ltd. (上海興尚企業管理諮詢有限公司) ("Shanghai Xingshang")	Interests in controlled corporations	13,297,378 H Shares	6.63	2.36
WANG Zhenting	Interests in controlled corporations	13,297,378 H Shares	6.63	2.36
LI Luqian	Interest of spouse	13,297,378 H Shares	6.63	2.36
Shanghai Xingpan Investment Management Consulting Co., Ltd. (上海興畔投資管理諮詢有限公司) ("Shanghai Xingpan")	Interests in controlled corporations	15,538,280 H Shares	7.75	2.76
NI Yuanyuan	Interests in controlled corporations; Interest of spouse	15,538,280 H Shares	7.75	2.76
LIU Qin	Interests in controlled corporations	15,538,280 H Shares	7.75	2.76
LOU Yiting	Interest of spouse	15,538,280 H Shares	7.75	2.76

OTHER INFORMATION

Name of Shareholder	Capacity/nature of interest	Number of Shares held	Approximate percentage of shareholding in the relevant proportion of Shares ⁽¹⁾ (%)	Approximate percentage of shareholding in the total issued share capital of our Company ⁽¹⁾ (%)
SHI Jianming	Interests in controlled corporations	15,538,280 H Shares	7.75	2.76
Tianjin SAIF Shengyuan Investment Management Center (Limited Partnership) (天津賽富盛元投資管理中心(有限合夥)) ⁽⁷⁾	Interests in controlled corporations	10,889,262 H Shares	5.43	1.93
YAN Andrew Y ⁽⁷⁾	Interests in controlled corporations	10,889,262 H Shares	5.43	1.93
Zheshang Venture Capital Co., Ltd. (浙商創投股份有限公司) (“Zheshang VC”) ⁽⁸⁾	Beneficial owner; Interests in controlled corporations	10,094,225 H Shares	5.03	1.79
Ningbo Meishan Bonded Area Dirui Investment Management Partnership (Limited Partnership) (寧波梅山保稅港區迪銳投資管理合夥企業(有限合夥)) ⁽⁹⁾	Interests in controlled corporations	10,694,479 H Shares	5.42	1.91
TANG Meng ⁽⁹⁾	Interests in controlled corporations	10,694,479 H Shares	5.42	1.91
ZHANG Xu ⁽¹⁰⁾	Interests in controlled corporations	12,285,138 H Shares	6.23	2.19

Notes:

- As of June 30, 2025, there were 563,779,000 Shares in total, including 363,186,467 Domestic Shares and 200,592,533 H Shares.
- Mr. Zhao Lu beneficially holds 93,042,388 Domestic Shares. Mr. Zhao is the executive partner of Shanghai Xiaoju, Shanghai Kunrui, Xinyu Haolin, Xinyu Qiwushi, Ruansu Enterprise Management, Xinyu Nuoming, Xinyu Xingmeng and Shanghai Kunrui, and is responsible for their respective management. As at June 30, 2025, he also held approximately 74.94% partnership interest in Ruansu Enterprise Management. Further, Mr. Zhao is the general partner of Zhoushan Yijin and Xinyu Shengkong, and is responsible for their respective management. As such, under the SFO, Mr. Zhao is deemed to be interested in the 85,160,640 Domestic Shares and 1,216,500 H Shares held by Shanghai Xiaoju, Shanghai Kunrui, Xinyu Haolin, Xinyu Qiwushi, Ruansu Enterprise Management, Xinyu Nuoming, Xinyu Xingmeng, Zhoushan Yijin and Xinyu Shengkong.

Ms. Tang Lili held 95% partnership interest in Zhoushan Yijin and 99% partnership interest in Xinyu Shengkong as their respective sole limited partner as of June 30, 2025. As such, under the SFO, Ms. Tang is deemed to be interested in the 23,585,382 Domestic Shares held by Zhoushan Yijin and Xinyu Shengkong. Besides, Ms. Tang is the spouse of Mr. Zhao. As such, she is deemed to be interested in the H Shares and the Domestic Shares in which Mr. Zhao is interested and is deemed to be interested.

OTHER INFORMATION

3. Linzhi Tencent Investment Management Co., Ltd. (林芝騰訊投資管理有限公司) is wholly owned by Shenzhen Tencent Industrial Investment Fund Co., Ltd. (深圳市騰訊產業投資基金有限公司), which is a subsidiary of Tencent Holdings Limited (a company listed on the Main Board of the Stock Exchange, stock codes: 700 (HKD counter) and 80700 (RMB counter)).
4. Suzhou Paiyi Venture Capital Partnership L.P. (蘇州湃益創業投資合夥企業(有限合夥)) is managed by its general partner, Suzhou Yaoyi Enterprise Management Co., Ltd. (蘇州垚益企業管理有限公司) which is wholly owned by Shenzhen Zeyi Consultancy Co., Ltd. (深圳市澤益諮詢有限公司). Suzhou Tencent Phase I Investment Fund Partnership (Limited Partnership) (蘇州騰訊一期跟投基金合夥企業(有限合夥)) is the largest limited partner of Suzhou Paiyi Venture Capital Partnership L.P..
5. The general partner of Jingwei Chuangteng is Jingwei Yuanchuang, whose general partner is Shanghai Jingwei, which was in turn held as to 80% by ZUO Lingye.

Besides, the general partner of Suzhou Jingwei Chuangbo Investment Center (Limited Partnership) (蘇州經緯創博投資中心(有限合夥)) is Suzhou Weichuang Investment Management Partnership (Limited Partnership) (蘇州緯創投資管理合夥企業(有限合夥)), whose general partner is Shanghai Jingyi Investment Management Co., Ltd. (上海經熠投資管理有限公司), which was in turn held as to 80% by ZUO Lingye.

As such, under the SFO, each of Jingwei Yuanchuang and Shanghai Jingwei is deemed to be interested in the 22,349,533 Domestic Shares and 28,100,879 H Shares held by Jingwei Chuangteng, and ZUO Lingye is deemed to be interested in the 23,908,953 Domestic Shares and 30,061,593 H Shares held by Jingwei Chuangteng and Suzhou Jingwei Chuangbo Investment Center (Limited Partnership).

6. The general partner of each Suzhou Northern Lights Zhengyuan Venture Capital Partnership (Limited Partnership) (蘇州北極光正源創業投資合夥企業(有限合夥)) and Suzhou Northern Lights Hongyuan Venture Capital Partnership (Limited Partnership) (蘇州北極光泓源創業投資合夥企業(有限合夥)) is Suzhou Boyuan Venture Capital Management Partnership (Limited Partnership) (蘇州柏源創業投資管理合夥企業(有限合夥)), whose general partner is Suzhou Songyuan Entrepreneurship Investment Management Co., Ltd. (蘇州松源創業投資管理有限公司), which was held as to 50% by ZHANG Pengpeng (張朋朋), 25% by LI Lixin (李立新) and 25% by YANG Lei (楊磊), respectively. As such, under the SFO, each of Suzhou Boyuan Venture Capital Management Partnership (Limited Partnership), Suzhou Songyuan Entrepreneurship Investment Management Co., Ltd. and ZHANG Pengpeng is deemed to be interested in the 15,930,449 Domestic Shares and 15,930,449 H Shares held by Suzhou Northern Lights Zhengyuan Venture Capital Partnership (Limited Partnership) and Suzhou Northern Lights Hongyuan Venture Capital Partnership (Limited Partnership).
7. The general partner of Suzhou SAIF Puxin Medical and Health Industry Investment Center (Limited Partnership) (蘇州賽富璞鑫醫療健康產業投資中心(有限合夥)) is Suzhou SAIF Puxin Venture Capital Center (Limited Partnership) (蘇州賽富璞鑫創業投資中心(有限合夥)), whose general partner is Tianjin SAIF Shengyuan Investment Management Center (Limited Partnership) (天津賽富盛元投資管理中心(有限合夥)), which is managed by its executive partner, YAN Andrew Y.

The general partner of Nanjing SAIF Hengzhun Venture Capital Fund (Limited Partnership) (南京賽富衡准創業投資基金(有限合夥)) is Jiaxing SAIF Hengshun Investment Management Partnership (Limited Partnership) (嘉興賽富恒順投資管理合夥企業(有限合夥)), whose general partner is Tianjin SAIF Shengyuan Investment Management Center (Limited Partnership).

The general partner of Huangshan SAIF Tourism Cultural Industry Development Fund (Limited Partnership) (黃山賽富旅遊文化產業發展基金(有限合夥)) is Mount Huangshan Saifu Fund Management Co., Ltd. (黃山賽富基金管理有限責任公司), which was held as to 80% by Tianjin SAIF Shengyuan Investment Management Center (Limited Partnership).

As such, under the SFO, each of Tianjin SAIF Shengyuan Investment Management Center (Limited Partnership) and YAN Andrew Y is deemed to be interested in the 10,889,262 H Shares held by Suzhou SAIF Puxin Medical and Health Industry Investment Center (Limited Partnership), Nanjing SAIF Hengzhun Venture Capital Fund (Limited Partnership) and Huangshan SAIF Tourism Cultural Industry Development Fund (Limited Partnership).

OTHER INFORMATION

8. Zhesang VC is a limited liability company listed on the National Equities Exchange And Quotations (stock code: 834089). It beneficially holds 1,609,427 H Shares.

The general partner of Hangzhou Yangjian Investment Partnership (Limited Partnership) (杭州仰健投資合夥企業(有限合夥)) is Zhejiang Haipeng Investment Management Co., Ltd. (浙江海鵬投資管理有限公司), which is a wholly-owned subsidiary of Zhesang VC.

The general partner of Hangzhou Qizhen Future Innovation Equity Investment Partnership (Limited Partnership) (杭州啟真未來創新股權投資合夥企業(有限合夥)) is Zhesang VC.

As such, under the SFO, Zhesang VC is deemed to be interested in the 8,484,798 H Shares held by Hangzhou Yangjian Investment Partnership (Limited Partnership) and Hangzhou Qizhen Future Innovation Equity Investment Partnership (Limited Partnership).

9. The general partner of each of Aochuan Bangde Investment Partnership (Limited Partnership) (蘇州市相城區奧傳邦德投資合夥企業(有限合夥)), Ningbo Jinjiao Langqiu Investment Partnership (Limited Partnership) (寧波金蛟朗秋投資合夥企業(有限合夥)) and Ningbo Xuri Xinzhu Investment Partnership (Limited Partnership) (寧波旭日新竹投資合夥企業(有限合夥)) is Ningbo Meishan Bonded Area Dirui Investment Management Partnership (Limited Partnership) (寧波梅山保稅港區迪銳投資管理合夥企業(有限合夥)), whose general partner is TANG Meng. As such, under the SFO, each of Ningbo Meishan Bonded Area Dirui Investment Management Partnership (Limited Partnership) and TANG Meng is deemed to be interested in the 8,505,665 Domestic Shares and 10,694,479 H Shares held by Aochuan Bangde Investment Partnership (Limited Partnership), Ningbo Jinjiao Langqiu Investment Partnership (Limited Partnership) and Ningbo Xuri Xinzhu Investment Partnership (Limited Partnership).
10. The general partner of Chengdu SBCVC Tiantou Venture Capital Center (Limited Partnership) (成都軟銀天投創業投資中心(有限合夥)) is Chongqing SBCVC Investment Management Co., Ltd. (重慶軟銀投資管理有限公司), which was held as to 95% by ZHANG Xu.

The general partner of Ningbo SBCVC Stable Growth Investment Partnership (Limited Partnership) (寧波軟銀穩定成長投資合夥企業(有限合夥)) is Shanghai Xinbo Jieyi Private Fund Management Partnership (Limited Partnership) (上海欣博傑益私募基金管理合夥企業(有限合夥)), whose general partner is Shanghai Guanhe Lanzheng Investment Management Co., Ltd (上海觀禾覽正投資管理有限公司), which was held as to 90% by ZHANG Xu.

The general partner of Jiaxing SBCVC Venture Capital Partnership (Limited Partnership) (嘉興軟銀創業投資合夥企業(有限合夥)) is Ningbo Ruanku Investment Co., Ltd. (寧波軟庫投資有限公司), which was held as to 60% by ZHANG Xu.

As such, under the SFO, ZHANG Xu is deemed to be interested in the 9,770,766 Domestic Shares and 12,285,138 H Shares held by Chengdu SBCVC Tiantou Venture Capital Center (Limited Partnership), Ningbo SBCVC Stable Growth Investment Partnership (Limited Partnership) and Jiaxing SBCVC Venture Capital Partnership (Limited Partnership).

11. All interests are long positions.

Save as disclosed above, as at June 30, 2025, the Company had not been notified by any other persons (other than the Directors, Supervisors or chief executives of the Company) who had an interest or short position in the Shares or underlying Shares of the Company which would fall to be disclosed under Divisions 2 and 3 of Part XV of the SFO, or which were required to be entered in the register required to be kept by the Company pursuant to Section 336 of the SFO.

OTHER INFORMATION

CHANGES IN INFORMATION OF DIRECTORS AND SUPERVISORS

There was no change in the information of the Directors and Supervisors required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules since the publication date of the 2024 annual report and up to the date of this interim report.

CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE LISTING RULES

The Company does not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

On behalf of the Board

Mr. ZHAO Lu

Chairman of the Board

Zhejiang, the PRC, August 28, 2025

REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

To the Board of Directors of Zhejiang Taimei Medical Technology Co., Ltd.

(incorporated in the People's Republic of China with limited liability)

INTRODUCTION

We have reviewed the interim financial information set out on pages 33 to 70, which comprises the interim condensed consolidated balance sheet of Zhejiang Taimei Medical Technology Co., Ltd. (the "Company") and its subsidiaries (together, the "Group") as at June 30, 2025 and the interim condensed consolidated income statement, the interim condensed consolidated statement of comprehensive loss, the interim condensed consolidated statement of changes in equity and the interim condensed consolidated statement of cash flows for the six-month period then ended, and selected explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 "Interim Financial Reporting". The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with International Accounting Standard 34 "Interim Financial Reporting". Our responsibility is to express a conclusion on this interim financial information based on our review and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information of the Group is not prepared, in all material respects, in accordance with International Accounting Standard 34 "Interim Financial Reporting".

PricewaterhouseCoopers

Certified Public Accountants

Hong Kong, August 28, 2025

INTERIM CONDENSED CONSOLIDATED INCOME STATEMENT

FOR THE SIX MONTHS ENDED JUNE 30, 2025

		Six months ended June 30, 2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
	Notes		
Revenue	6	244,221	272,784
Cost of sales	7	(144,033)	(161,840)
Gross profit		100,188	110,944
Selling expenses	7	(37,573)	(51,158)
Administrative expenses	7	(57,679)	(217,186)
Research and development expenses	7	(37,705)	(50,924)
Net impairment losses on financial assets and contract assets		(5,454)	(1,344)
Other income	8	2,445	9,824
Other (losses)/gains – net	9	(12,932)	7,849
Operating loss		(48,710)	(191,995)
Finance income		19,980	16,929
Finance cost		(579)	(251)
Finance income – net	10	19,401	16,678
Loss before income tax		(29,309)	(175,317)
Income tax expenses	11	–	–
Loss for the period		(29,309)	(175,317)
Loss is attributable to:			
Owners of the Company		(22,802)	(171,126)
Non-controlling interests		(6,507)	(4,191)
		(29,309)	(175,317)
Loss per share for loss attributable to equity holders of the Company			
Basic and diluted loss per share (RMB)	12	(0.04)	(0.32)

The above interim condensed consolidated income statement should be read in conjunction with the accompanying notes.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS

FOR THE SIX MONTHS ENDED JUNE 30, 2025

	Six months ended June 30,	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Loss for the period	(29,309)	(175,317)
Other comprehensive income/(loss)		
<i>Item that may be reclassified to profit or loss</i>		
Exchange differences on translation of foreign operations	10,539	(2,098)
Other comprehensive income/(loss) for the period, net of taxes	10,539	(2,098)
Total comprehensive loss for the period	(18,770)	(177,415)
Total comprehensive loss for the period is attributable to:		
Equity holders of the Company	(12,423)	(173,240)
Non-controlling interests	(6,347)	(4,175)
	(18,770)	(177,415)

The above interim condensed consolidated statement of comprehensive loss should be read in conjunction with the accompanying notes.

INTERIM CONDENSED CONSOLIDATED BALANCE SHEET

AS AT JUNE 30, 2025

	Notes	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Assets			
Non-current assets			
Property, plant and equipment	14	10,295	12,201
Right-of-use assets	15	17,819	23,003
Intangible assets	16	56,351	58,181
Long-term receivables	21	11,839	12,712
		96,304	106,097
Current assets			
Contract fulfilment cost	18	6,172	3,546
Contract assets	6(a)	19,722	16,614
Trade and notes receivables	19	165,861	170,013
Other receivables and prepayments	20	81,194	82,444
Financial assets at fair value through profit or loss		—	120,792
Short-term treasury investments	22	160,083	159,374
Restricted cash	23	100	5,100
Short-term bank deposits	23	736,071	599,920
Cash and cash equivalents	23	253,013	319,297
		1,422,216	1,477,100
Total assets		1,518,520	1,583,197
Equity			
Equity attributable to equity holders of the Company			
Share capital	24	563,779	563,779
Other reserves	25	2,295,802	2,295,189
Currency translation reserves		12,298	1,919
Accumulated losses		(1,725,879)	(1,703,077)
		1,146,000	1,157,810
Non-controlling interests		70,416	76,763
Total equity		1,216,416	1,234,573

INTERIM CONDENSED CONSOLIDATED BALANCE SHEET

AS AT JUNE 30, 2025

	Notes	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Liabilities			
Non-current liabilities			
Lease liabilities	15	7,976	13,283
Deferred revenue	29	7,402	7,402
Warrant liabilities	26	35,318	35,347
		50,696	56,032
Current liabilities			
Borrowings		—	10,004
Trade and other payables	28	170,913	184,418
Lease liabilities	15	10,796	11,471
Contract liabilities	6(b)	69,699	86,699
		251,408	292,592
Total liabilities		302,104	348,624
Total equity and liabilities		1,518,520	1,583,197

The above interim condensed consolidated balance sheet should be read in conjunction with the accompanying notes.

The condensed consolidated interim financial information on pages 33 to 70 was approved and authorised for issue by the Board of Directors of the Company on August 28, 2025 and was signed on its behalf by:

Zhao Lu
Director

Ni Xiaomei
Director

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED JUNE 30, 2025

		Equity attributable to owners of the Company						
		Share capital	Other reserves	Currency translation reserves	Accumulated losses	Total	Non-controlling interests	Total equity
	Notes	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
(Unaudited)								
As at January 1, 2025		563,779	2,295,189	1,919	(1,703,077)	1,157,810	76,763	1,234,573
Comprehensive loss								
Loss for the period		-	-	-	(22,802)	(22,802)	(6,507)	(29,309)
Exchange differences on translation of foreign operations		-	-	10,379	-	10,379	160	10,539
Total comprehensive loss		-	-	10,379	(22,802)	(12,423)	(6,347)	(18,770)
Transactions with owners								
Share-based payments	7, 27	-	613	-	-	613	-	613
Total transactions with owners		-	613	-	-	613	-	613
As at June 30, 2025		563,779	2,295,802	12,298	(1,725,879)	1,146,000	70,416	1,216,416
(Unaudited)								
As at January 1, 2024		538,000	1,922,646	6,149	(1,488,468)	978,327	63,786	1,042,113
Comprehensive loss								
Loss for the period		-	-	-	(171,126)	(171,126)	(4,191)	(175,317)
Exchange differences on translation of foreign operations		-	-	(2,114)	-	(2,114)	16	(2,098)
Total comprehensive loss		-	-	(2,114)	(171,126)	(173,240)	(4,175)	(177,415)
Transactions with owners								
Share-based payments	7, 27	-	22,242	-	-	22,242	-	22,242
Transactions with non-controlling interests		-	77,022	-	-	77,022	15,814	92,836
Total transactions with owners		-	99,264	-	-	99,264	15,814	115,078
As at June 30, 2024		538,000	2,021,910	4,035	(1,659,594)	904,351	75,425	979,776

The above interim condensed consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2025

		Six months ended June 30, 2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
	Notes		
Cash flows from operating activities			
Cash used in operations		(47,927)	(132,927)
Net cash used in operating activities		(47,927)	(132,927)
Cash flows from investing activities			
Purchase of property, plant and equipment	14	(1,164)	(1,213)
Purchase of intangible assets	16	(285)	–
Proceeds from disposal of property, plant and equipment		5	–
Placement of short-term bank deposits		(1,357,156)	(576,907)
Redemption of short-term bank deposits		1,199,585	257,142
Interest income		37,318	30,364
Purchase of short-term investments measured at fair value through profit or loss	4(c)	–	(235,000)
Proceeds from disposal of short-term investments measured at fair value through profit or loss	4(c)	121,915	221,159
Net cash generated/(used in) from investing activities		218	(304,455)
Cash flows from financing activities			
Repayments of borrowings		(10,000)	–
Interest paid		(134)	–
Principal elements of lease payments		(5,982)	(12,036)
Interests elements of lease payments		(449)	(251)
Payment of listing expense in relation to global offering		–	(3,107)
Net cash used in financing activities		(16,565)	(15,394)
Net decrease in cash and cash equivalents		(64,274)	(452,776)
Cash and cash equivalents at beginning of period		319,297	517,924
Effect of foreign exchange rates changes		(2,010)	786
Cash and cash equivalents at end of period		253,013	65,934

The above interim condensed consolidated statement of cash flow should be read in conjunction with the accompanying notes.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

1 GENERAL INFORMATION

Zhejiang Taimei Medical Technology Co., Ltd. (浙江太美醫療科技股份有限公司) (the “Company”) was established under its former name, Jiaying Taimei Medical Technology Co., Ltd. (嘉興太美醫療科技有限公司), as a limited liability company in the People’s Republic of China (the “PRC”) on June 6, 2013. The Company completed its conversion into a joint stock limited company on September 11, 2020.

The Company and its subsidiaries (together, the “Group”) are primarily engaged in providing digital solutions for life sciences R&D and commercialisation mainly in the PRC and certain overseas countries and regions.

The ultimate controlling shareholder of the Group is Mr. Zhao Lu (趙璐先生).

On October 8, 2024, the Company completed its IPO and was successfully listed on Main Board of the Stock Exchange of Hong Kong Limited.

The condensed consolidated interim financial information is presented in thousands of Renminbi (“RMB’000”), unless otherwise. The condensed consolidated interim financial information was approved for issue by the Board of Directors on August 28, 2025.

2 BASIS OF PREPARATION

This condensed consolidated interim financial information for the six months ended June 30, 2025 has been prepared in accordance with International Accounting Standards (“IAS”) 34, “Interim Financial Reporting” issued by the International Accounting Standards Board (“IASB”). This report is to be read in conjunction with the consolidated financial statements of the Group for the year ended December 31, 2024, which have been prepared in accordance with IFRS Accounting Standards (“IFRS”).

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

3 NEW STANDARDS AND INTERPRETATIONS

Except as described below, the accounting policies applied are consistent with those of the annual financial statements for the year ended December 31, 2024, as described in those annual financial statements.

(a) Amended standard adopted by the Group

The Group has applied the following amendment for the first time for its financial year commencing 1 January 2025:

		Effective for accounting periods beginning on or after
IAS 21 (Amendment)	Lack of Exchangeability	January 1, 2025

The adoption of the amended standard does not have significant impact on the condensed consolidated interim financial information of the Group.

(b) Amendments to existing standards have not yet been adopted

The followings new standards and amendments to standards have not come into effect for the financial year beginning January 1, 2025 and have not been early adopted by the Group in preparing the condensed consolidated interim financial information. None of these is expected to have a significant effect on the condensed consolidated interim financial information of the Group.

		Effective for accounting periods beginning on or after
IFRS 7 and IFRS 9 (Amendments)	Amendments to the Classification and Measurement of Financial Instruments	January 1, 2026
IFRS 7 and IFRS 9 (Amendments)	Contracts Referencing Nature-dependent Electricity	January 1, 2026
Annual Improvements to IFRS Accounting Standards	Annual Improvements to IFRS Accounting Standards – Volume 11	January 1, 2026
IFRS 19	Subsidiaries without public accountability: disclosures	January 1, 2027
IFRS 18	Presentation and disclosure in financial statements	January 1, 2027
IFRS 10 and IAS 28 (Amendments)	Sales or contribution assets between an investor and its associate or joint venture	To be determined

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS

This note provides an update on the judgements and estimates made by the Group in determining the fair values of the financial instruments since the last annual financial report.

(a) Fair value hierarchy

To provide an indication about the reliability of the inputs used in determining fair value, the Group has classified its financial instruments into the three levels prescribed under the accounting standards. An explanation of each level follows underneath the table.

The following table presents the Group's financial assets and financial liabilities measured and recognised at fair value at June 30, 2025 and December 31, 2024 on a recurring basis:

	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
(Unaudited)				
At June 30, 2025				
Liabilities:				
– Warrant liabilities	–	–	35,318	35,318
	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
(Audited)				
At December 31, 2024				
Assets:				
– Financial assets at FVPL	–	–	120,792	120,792
Liabilities:				
– Warrant liabilities	–	–	35,347	35,347

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS (Continued)

(a) Fair value hierarchy (Continued)

The Group's policy is to recognise transfers into and transfers out of fair value hierarchy levels as at the end of the reporting period.

Level 1: The fair value of financial instruments traded in active markets (such as publicly traded derivatives, and trading securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.

Level 2: The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives) is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted debt and equity investment.

(b) Valuation techniques used to determine fair values

Specific valuation techniques used to value financial instruments include:

- Quoted market prices or dealer quotes for similar instruments; and
- Other techniques, such as discounted cash flow analysis, are used to determine fair value for the remaining financial instruments.

The fair value of trade and notes receivables, other receivables, long-term receivables, short-term treasury investments, short-term bank deposits, restricted cash, cash and cash equivalents, trade and other payables approximated to their carrying amounts.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS (Continued)

(c) Fair value measurements using significant unobservable inputs (level 3)

The following table presents the changes in level 3 instruments for the six months ended June 30, 2025:

	Short-term investment measured at fair value through profit and loss RMB'000	Contingent consideration RMB'000	Warrant liabilities (Note 26) RMB'000	Total RMB'000
(Unaudited)				
At January 1, 2025	120,792	–	(35,347)	85,445
Disposals	(121,915)	–	–	(121,915)
Fair value changes	1,123	–	29	1,152
At June 30, 2025	–	–	(35,318)	(35,318)
(Unaudited)				
At January 1, 2024	278,769	2,057	(33,735)	247,091
Additions	235,000	–	–	235,000
Disposals	(221,159)	–	–	(221,159)
Fair value changes	6,948	6	(936)	6,018
At June 30, 2024	299,558	2,063	(34,671)	266,950

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS (Continued)

(c) Fair value measurements using significant unobservable inputs (level 3) (Continued)

(i) Valuation inputs and relationships to fair value

The following table summarises the quantitative information about the significant unobservable inputs used in level 3 fair value measurements:

At June 30, 2025

Description	Unobservable inputs	Range of inputs	Relationship of unobservable inputs to fair value
Warrant liabilities	Discount rate	1.34%-1.35%	The higher the discount rate, the lower the fair value

At December 31, 2024

Description	Unobservable inputs	Range of inputs	Relationship of unobservable inputs to fair value
Wealth management products	Expected rate of return	2.80%-3.82%	The higher the expected rate of return, the higher the fair value
Warrant liabilities	Discount rate	1.08%-1.14%	The higher the discount rate, the lower the fair value

If the discount rate of warrant liabilities which measured at fair value through profit or loss held by the Group had been 1% lower/higher, the loss before income tax for the six months ended June 30, 2025 would have been approximately RMB344,000 higher/lower (for six months ended June 30, 2024: RMB342,000).

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

5 SEGMENT INFORMATION

The Group's business activities are mainly in providing cloud-based software products including software-as-a-service products ("SaaS products") and customised products, digital services and others, for which discrete financial information is available, are regularly reviewed and evaluated by the executive directors of the Company, who are the chief operating decision makers. As a result of this evaluation, the executive directors of the Company consider that the Group's operation is operated and managed as a single segment and no segment information is presented, accordingly.

For the six months ended June 30, 2025, there was no revenue derived from transactions with a single external customer which amounted to 10% or more of the Group's revenue.

(a) Geographical information

The Group mainly operates its businesses in mainland China. The following table shows the Group's total consolidated revenue by location of the customers during the six months ended June 30, 2025:

	Six months ended June 30, 2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Mainland China	238,577	267,292
Korea	1,058	2,292
Singapore	1,872	1,750
Europe	1,360	1,030
Others	1,354	420
	244,221	272,784

(b) Non-current assets

The total of the non-current assets including property, plant and equipment, right-of-use assets and intangible assets as at June 30, 2025, broken down by the location of the assets, is as follows:

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Mainland China	83,283	90,839
Singapore	815	1,296
The United States	367	1,250
	84,465	93,385

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

6 REVENUE

Revenue for the six months ended June 30, 2025 is as follows:

	Six months ended June 30, 2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Cloud-based software products		
– SaaS products	82,425	81,564
– Customised products	12,171	15,993
Digital services	149,371	175,227
Other services	254	–
	244,221	272,784

Disaggregation of revenue from contracts with customers by the timing of revenue recognition is as follows:

	Six months ended June 30, 2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Revenue		
– recognised over time	238,162	265,999
– recognised point in time	6,059	6,785
	244,221	272,784

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

6 REVENUE (Continued)

(a) Contract assets

Contract assets are reclassified to trade receivables when the Group's right to the considerations becomes unconditional. The Group has recognised the following contract assets with customers:

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Current assets	20,734	17,506
Loss allowance	(1,012)	(892)
	19,722	16,614

(b) Contract liabilities

The Group has recognised the following liabilities related to contracts with customers:

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Current liabilities	69,699	86,699

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

7 EXPENSES BY NATURE

The expenses charged to cost of sales, selling expenses, administrative expenses and research and development expenses are analysed below:

	Six months ended June 30,	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Employee benefit expenses (excluding share-based payments)	152,050	209,643
Clinical research related costs	70,322	74,207
Costs of IT infrastructure and data service	14,423	17,728
Office, business development and travelling expenses	11,708	12,749
Consulting and professional service fees	6,827	3,666
Depreciation of right-of-use assets (Note 15(c))	5,223	13,045
Depreciation of property, plant and equipment (Note 14)	3,068	10,609
Amortisation of intangible assets (Note 16)	2,115	2,107
Short-term rental expenses	644	757
Share-based payments (Note 27(c))	613	22,242
Share-based compensation to certain shareholders	–	92,836
Listing expenses in relation to global offering	–	10,986
Other expenses	9,997	10,533
	276,990	481,108

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

8 OTHER INCOME

	Six months ended June 30,	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Government grants (a)	1,734	8,541
Others	711	1,283
	2,445	9,824

- (a) Governments grants received during the period primarily comprised the financial subsidies received from various local government authorities in mainland China. There are no unfulfilled conditions or contingencies relating to these income.

9 OTHER (LOSSES)/GAINS – NET

	Six months ended June 30,	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Fair value gains on financial assets at fair value through profit or loss	1,123	6,954
Net foreign exchange (losses)/gains	(16,075)	5,275
Fair value gains/(losses) of warrant liabilities (Note 4(c))	29	(936)
Others	1,991	(3,444)
	(12,932)	7,849

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

10 FINANCE INCOME – NET

	Six months ended June 30,	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Finance income		
Interest income	19,775	16,929
Accretion income for long-term receivables	205	–
	19,980	16,929
Finance costs		
Interest expenses on bank borrowings	(130)	–
Interest charges on lease liabilities (Note 15)	(449)	(251)
	(579)	(251)
Finance income – net	19,401	16,678

11 INCOME TAX EXPENSE

(i) Corporate income tax in mainland China (“CIT”)

The income tax provision of the Group in respect of its operations in the mainland China was subject to statutory tax rate of 25% on the assessable profits, based on the existing legislation, interpretations and practices in respect thereof.

The Company, Taimei Intelligence Pharmaceutical R&D Co., Ltd., Hangzhou Taimei Xingcheng Pharmaceutical Technology Co., Ltd., Shanghai Taimei Xingyun Digital Technology Co., Ltd. and Shanghai Taimei Digital Technology Co., Ltd. were qualified as “High and New Technology Enterprises” (“HNTEs”) under the relevant PRC laws and regulations. Accordingly, these entities were entitled to a preferential income tax rate of 15% on the assessable profits during the six months ended June 30, 2025.

During the six months ended June 30, 2025, certain subsidiaries in the mainland China that qualified as “small low-profit enterprises” under the Enterprise Income Tax Law of the PRC enjoyed a preferential income tax rate of 20% (for the six months ended June 30, 2024: 20%).

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

11 INCOME TAX EXPENSE (Continued)

(ii) Singapore income tax

Singapore income tax rate is 17%. No Singapore profits tax was provided for as there was no estimated assessable profit that was subject to Singapore profits tax during the six months ended June 30, 2025 (for the six months ended June 30, 2024: 17%).

(iii) The United States income tax

The United States income tax rate divided into federal tax and state tax. The Federal CIT is 21% and the State CITs range from 1% to 12%. No United States profits tax was provided for as there was no estimated assessable profit that was subject to the United States profits tax during the six months ended June 30, 2025 (for the six months ended June 30, 2024: 21% and 1%-12% respectively).

12 LOSS PER SHARE

Basic

The basic loss per share is calculated by dividing the loss attributable to owners of the Company by the weighted average number of shares in issue during the six months ended June 30 2025.

	Six months ended June 30,	
	2025	2024
	(Unaudited)	(Unaudited)
Loss attributable to owners of the Company (RMB'000)	(22,802)	(171,126)
Weighted average number of ordinary shares in issue (thousand shares)	563,779	538,000
Basic loss per share (expressed in RMB per share)	(0.04)	(0.32)

Diluted

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. As the Group incurred losses during the six months ended June 30, 2025, the potential ordinary shares, i.e. restricted shares issued under the Company's and the subsidiary's share incentive plan, were not included in the calculation of diluted loss per share as their inclusion would be anti-dilutive. Accordingly, diluted loss per share for the six months ended June 30, 2025 is the same as basic loss per share (for the six months ended June 30, 2024: same as basic loss per share).

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

13 DIVIDENDS

No dividend had been declared or paid by the Company during the six months ended June 30, 2025 (for the six months ended June 30, 2024: nil).

14 PROPERTY, PLANT AND EQUIPMENT

	Server and electronic equipment	Furniture and office equipment	Transportation equipment and vehicles	Leasehold improvements	Total
(Audited)					
At December 31, 2024					
Cost	16,153	5,088	2,449	51,371	75,061
Accumulated depreciation	(12,420)	(2,970)	(1,691)	(45,779)	(62,860)
Net book amount	3,733	2,118	758	5,592	12,201
(Unaudited)					
Six months ended June 30, 2025					
Opening net book amount	3,733	2,118	758	5,592	12,201
Additions	1,164	–	–	–	1,164
Disposals	(16)	–	–	–	(16)
Depreciation charge (Note 7)	(1,259)	(413)	(110)	(1,286)	(3,068)
Currency translation differences	1	–	(1)	14	14
Closing net book amount	3,623	1,705	647	4,320	10,295
(Unaudited)					
At June 30, 2025					
Cost	17,206	5,088	2,447	51,417	76,158
Accumulated depreciation	(13,583)	(3,383)	(1,800)	(47,097)	(65,863)
Net book amount	3,623	1,705	647	4,320	10,295

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

14 PROPERTY, PLANT AND EQUIPMENT (Continued)

During the six months ended June 30, 2025, depreciation charges were expensed off in the following categories in the interim condensed consolidated income statement:

	Six months ended June 30, 2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Cost of sales	295	558
Selling expenses	462	554
Administrative expenses	2,126	8,982
Research and development expenses	185	515
	3,068	10,609

15 RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

Right-of-use assets includes leased buildings.

(a) Amounts recognized in the interim condensed consolidated balance sheet

The interim condensed consolidated balance sheet shows the following amounts relating to leases:

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Right-of-use assets		
Leased buildings	17,819	23,003
Lease liabilities		
Current	10,796	11,471
Non-current	7,976	13,283
	18,772	24,754

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

15 RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Continued)

(b) Amounts recognized in the interim condensed consolidated income statement

The interim condensed consolidated income statement shows the following amounts relating to leases:

	Six months ended June 30, 2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Depreciation charge of right-of-use assets		
Leased buildings	5,223	13,045
Interest expense (included in finance income – net)	449	251

The total cash outflow for leases for the six months ended June 30, 2025 was RMB7,075,000 (for the six months ended June 30, 2024: RMB13,044,000).

(c) The movement in right-of-use assets in the interim condensed consolidated balance sheet are as follows:

	Total RMB'000
(Audited)	
At December 31, 2024	
Cost	42,750
Accumulated depreciation	(19,747)
Net book amount	23,003
(Unaudited)	
Six months ended June 30, 2025	
Opening net book amount	23,003
Depreciation charge (Note 7)	(5,223)
Currency translation differences	39
Closing net book amount	17,819
(Unaudited)	
At June 30, 2025	
Cost	42,877
Accumulated depreciation	(25,058)
Net book amount	17,819

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

15 RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Continued)

- (c) The movement in right-of-use assets in the interim condensed consolidated balance sheet are as follows: (Continued)

During the six months ended June 30, 2025, depreciation charges were expensed off in the following categories in the interim condensed consolidated income statement:

	Six months ended June 30,	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Cost of sales	1,801	3,962
Selling expenses	627	978
Administrative expenses	1,834	6,527
Research and development expenses	961	1,578
	5,223	13,045

16 INTANGIBLE ASSETS

	Goodwill (a)	Software	Patent	Total
	RMB'000	RMB'000	RMB'000	RMB'000
(Audited)				
At December 31, 2024				
Cost	161,126	12,951	29,900	203,977
Accumulated amortisation	–	(4,144)	(16,330)	(20,474)
Accumulated impairment	(124,118)	–	(1,204)	(125,322)
Net book amount	37,008	8,807	12,366	58,181
(Unaudited)				
Six months ended June 30, 2025				
Opening net book amount	37,008	8,807	12,366	58,181
Additions	–	285	–	285
Amortisation charge (Note 7)	–	(715)	(1,400)	(2,115)
Closing net book amount	37,008	8,377	10,966	56,351
(Unaudited)				
At June 30, 2025				
Cost	161,126	13,236	29,900	204,262
Accumulated amortisation and impairment	(124,118)	(4,859)	(18,934)	(147,911)
Net book amount	37,008	8,377	10,966	56,351

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

16 INTANGIBLE ASSETS (Continued)

During the six months ended June 30, 2025, amortization charges were expensed off in the following categories in the interim condensed consolidated income statement:

	Six months ended June 30,	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Cost of sales	87	73
Selling expenses	22	24
Administrative expenses	1,819	1,824
Research and development expenses	187	186
	2,115	2,107

(a) Goodwill

The goodwill balance arose from the acquisitions of Taimei Xinghuan on June 28, 2019 and Beijing Nuoming Technology Co., Ltd ("Beijing Nuoming") on November 29, 2019, amounting to RMB139,646,000 and RMB21,480,000, respectively. Taimei Xinghuan is primarily engaged in provision of pharmaceutical marketing solutions. Beijing Nuoming is mainly engaged in provision of institution digitalisation solutions. The following is a summary of goodwill allocation for CGUs:

	As at June 30, 2025	As at December 31, 2024
	RMB'000	RMB'000
	(Unaudited)	(Audited)
Cost		
Taimei Xinghuan	139,646	139,646
Beijing Nuoming	21,480	21,480
	161,126	161,126
Accumulated impairment		
Taimei Xinghuan	(102,638)	(102,638)
Beijing Nuoming	(21,480)	(21,480)
	(124,118)	(124,118)
Closing net book amount	37,008	37,008

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

17 DEFERRED INCOME TAX

The analysis of deferred income tax assets and deferred income tax liabilities is as follows:

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Deferred income tax assets:		
– to be recovered within 12 months	3,318	3,633
– to be recovered after more than 12 months	1,024	1,858
Offset by deferred income tax liabilities	(4,342)	(5,491)
Net deferred income tax assets	–	–
Deferred income tax liabilities:		
– to be recovered within 12 months	(1,413)	(1,689)
– to be recovered after more than 12 months	(2,929)	(3,802)
Offset by deferred income tax assets	4,342	5,491
Net deferred income tax liabilities	–	–

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

17 DEFERRED INCOME TAX (Continued)

The gross movements on the deferred income tax account are as follows:

Deferred income tax assets	Tax losses RMB'000	Credit loss allowance RMB'000	Lease liabilities RMB'000	Total RMB'000
(Unaudited)				
At January 1, 2025	149	1,860	3,482	5,491
Charged to the interim condensed consolidated income statement	(149)	(181)	(819)	(1,149)
At June 30, 2025	–	1,679	2,663	4,342
(Unaudited)				
At January 1, 2024	2,311	2,083	3,351	7,745
Credit to the interim condensed consolidated income statement	15	114	2,679	2,808
At June 30, 2024	2,326	2,197	6,030	10,553

Deferred income tax liabilities	Fair value adjustment on assets upon acquisition RMB'000	Right-of- use assets RMB'000	Fair value changes on financial assets carried at FVPL RMB'000	Total RMB'000
(Unaudited)				
At January 1, 2025	(1,855)	(3,517)	(119)	(5,491)
Credit to the interim condensed consolidated income statement	210	820	119	1,149
At June 30, 2025	(1,645)	(2,697)	–	(4,342)
(Unaudited)				
At January 1, 2024	(2,277)	(4,632)	(836)	(7,745)
Credit/(charged) to the interim condensed consolidated income statement	212	(2,356)	(664)	(2,808)
At June 30, 2024	(2,065)	(6,988)	(1,500)	(10,553)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

18 CONTRACT FULFILMENT COST

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Contract fulfilment cost	6,172	3,546
Less: allowance for impairment of inventories	—	—
	6,172	3,546

Contract fulfilment cost is recognised from the costs incurred to fulfill contracts of customised software, which will be recognised to cost of sales mainly within 2-6 months when the Group's related performance obligations are satisfied and hence the related revenue is recognised.

19 TRADE AND NOTES RECEIVABLES

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Notes receivables (a)	907	1,958
Provision for impairment	—	—
	907	1,958
Trade receivables (b)	190,355	188,684
Provision for impairment	(25,401)	(20,629)
	164,954	168,055
	165,861	170,013

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

19 TRADE AND NOTES RECEIVABLES (Continued)

(a) Notes receivables

The aging of notes receivables is within 180 days, which is within the Group's credit terms.

(b) Trade receivables

The credit terms given to trade customers are determined on an individual basis with normal credit period mainly around 30 to 120 days. The aging analysis of the trade receivables based on date of revenue recognition is as follows:

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Up to 3 months	83,279	79,957
3 months to 6 months	32,854	38,446
6 months to 1 year	31,124	28,371
1 to 2 years	28,366	29,904
2 to 3 years	11,051	9,021
More than 3 years	3,681	2,985
	190,355	188,684

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

20 OTHER RECEIVABLES AND PREPAYMENTS

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Other receivables		
– refundable deposits	7,847	7,671
– others	1,356	1,199
Gross other receivables	9,203	8,870
Less: provision for impairment	(323)	(322)
	8,880	8,548
Prepayments for products and services	52,736	51,351
Deductible input VAT	19,578	22,545
	81,194	82,444

As at June 30, 2025, the fair values of other receivables of the Group, except for the prepayments and deductible input VAT which are not financial assets, approximated their carrying amounts.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

21 LONG-TERM RECEIVABLES

Long-term receivables represented the receivables due for settlement by instalments, which are generally between 1 to 5 years. Long-term receivables contain significant financing components. Accordingly, these receivables are recognised initially at fair value and subsequently at amortised cost using the effective interest method. The portion due for settlement within 1 year is reclassified to trade receivables. The balance of long-term receivables was analysed in the following table.

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Payment by instalment sales contract	13,725	15,529
Less: due within one year	(1,807)	(2,729)
	11,918	12,800
Less: provision for impairment	(79)	(88)
	11,839	12,712

22 SHORT-TERM TREASURY INVESTMENTS

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Short-term treasury investments (a)		
– principal deposits	156,836	158,472
– interest receivable	3,472	1,137
Gross short-term treasury investments	160,308	159,609
Less: provision for impairment	(225)	(235)
	160,083	159,374

- (a) Short-term treasury investments included several fund products. These products were all redeemable at any time with a fixed interest return of 3%. The underlying assets of these products were primary short-term United States treasury bonds.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

23 CASH AND CASH EQUIVALENTS, RESTRICTED CASH AND SHORT-TERM BANK DEPOSITS

Cash and cash equivalents

	June 30, 2025 RMB'000 (Unaudited)	December 31, 2024 RMB'000 (Audited)
Cash at bank and in hand	989,184	924,317
Less: restricted cash (a)	(100)	(5,100)
Less: short-term bank deposits with initial term of over three months (b)	(736,071)	(599,920)
Cash and cash equivalents	253,013	319,297

(a) Restricted cash

As at June 30, 2025, RMB100,000 was restricted guarantee deposits at bank for letters of guarantee (December 31, 2024: RMB100,000 restricted guarantee deposits at bank for letters of guarantee and RMB5,000,000 due to an outstanding litigation).

The court of the litigation ruled to freeze the Group's bank deposits of RMB5,000,000 during the year ended December 31, 2023 as a provisional measure to preserve property before the decision of the litigation, which has no bearing on the merits of the claim. The litigation was resolved and the related restricted cash was released during the six months ended June 30, 2025.

(b) Short-term bank deposits were deposits with initial terms of over three months and were neither past due nor impaired. The directors of the Company considered that the carrying amount of the short-term bank deposits with initial terms of over three months approximated to their fair values as at June 30, 2025.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

24 SHARE CAPITAL

	Number of ordinary shares	Share capital RMB'000 (Unaudited)
At January 1, 2025, and June 30, 2025	563,779,000	563,779
At January 1, 2024, and June 30, 2024	538,000,000	538,000

25 OTHER RESERVES

	Share premium RMB'000	Capital reserve RMB'000	Share-based payments RMB'000	Total RMB'000
(Unaudited)				
At January 1, 2025	1,388,579	295,295	611,315	2,295,189
Share-based payments (Note 27)	–	–	613	613
At June 30, 2025	1,388,579	295,295	611,928	2,295,802
(Unaudited)				
At January 1, 2024	1,129,641	218,273	574,732	1,922,646
Share-based payments (Note 27)	–	–	2,363	2,363
Share-based payments to Mr. Zhao Lu	–	–	19,879	19,879
Transaction with non-controlling interests	–	77,022	–	77,022
As at June 30, 2024	1,129,641	295,295	596,974	2,021,910

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

26 WARRANT LIABILITIES

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Warrant liabilities (a)	35,318	35,347

- (a) During the year ended December 31, 2022, third-party investors (the “Non-controlling Shareholders”) subscribed for 21.49% of the equity interest in one subsidiary of the Group, by way of capital injection for an aggregate amount of USD50,000,000 (equivalent to RMB330,140,000). Pursuant to the agreement entered into between the Non-controlling Shareholders and the subsidiary, a warrant was issued to the Non-controlling Shareholders that they had right to subscribe new shares (an aggregate amount of subscription price being less than USD20,000,000) in the subsequent round of the subsidiary’s equity financing with an 80% financing price of any other investors in such round. Proceeds received from the Non-controlling Shareholders were recorded in the capital reserve, the non-controlling interests and warrant liabilities. Since the directors believe that the subsidiary of the Group will not start the subsequent round of equity financing before June 30, 2026, the warrant liabilities is classified as non-current liabilities with maturity of over 1 year.

Warrant liabilities were initially recognised at fair value of RMB28,796,000 and subsequently re-measured to their fair values at June 30, 2025. Changes of fair value were recorded in “other gains – net” in interim condensed consolidated income statements (Note 9).

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

27 SHARE-BASED PAYMENTS

Starting from 2016, the board of directors approved share award schemes ("restricted shares") for the purpose of providing incentive for certain directors, senior management members and employees contributing to the Group. The Group receives services from employees as consideration for equity instruments of the Company or a certain subsidiary under the above schemes.

The restricted shares awarded vest in tranches from the grant date over a certain service period. Once the vesting conditions of restricted shares are met, ordinary shares are considered duly and validly issued to the holder, and free of restrictions on transfer.

(a) Restricted shares issued by the Company

Movements in the number of outstanding restricted shares of the Company during the six months ended June 30, 2025 are as follows:

	Number of restricted shares
(Unaudited)	
At January 1, 2025	174,001
Granted	—
Vested	—
Forfeited	—
At June 30, 2025	174,001

The fair value of restricted shares at the grant date was determined by reference to the fair value of the underlying ordinary shares of the Company on the respective dates of grant.

Restricted shares of the Company outstanding at the end of the period have the following vesting period and exercise prices:

Grant date	Vesting period	Exercise price (RMB)	Number of restricted shares	
			As at June 30, 2025 (Unaudited)	As at December 31, 2024 (Audited)
October 15, 2023	3 years	0.86	174,001	174,001
			174,001	174,001

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

27 SHARE-BASED PAYMENTS (Continued)

(b) Restricted shares issued by a subsidiary

Movements in the number of outstanding restricted shares of a subsidiary during the six months ended June 30, 2025 are as follows:

	Number of restricted shares
(Unaudited)	
At January 1, 2025	450,500
Granted	—
Vested	—
Forfeited	—
At June 30, 2025	450,500

The fair value of restricted shares at the grant date was determined by reference to the fair value of the underlying ordinary shares of a subsidiary on the dates of grant.

Restricted shares of a subsidiary outstanding at the end of the period have the following vesting period and exercise prices:

Grant date	Vesting period	Exercise price (RMB)	Number of restricted shares	
			As at June 30, 2025 (Unaudited)	As at December 31, 2024 (Audited)
November 18, 2021	5 years	2.00	50,500	50,500
November 8, 2022	5 years	1.00	400,000	400,000
			450,500	450,500

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

27 SHARE-BASED PAYMENTS (Continued)

(c) Share-based payments recorded during six months ended June 30, 2025

During the six months ended June 30, 2025, the amounts of share-based payments to employees were charged in the following categories in the interim condensed consolidated income statements:

	Six months ended June 30,	
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Selling expenses	–	3,099
Administrative expenses	599	18,158
Research and development expenses	14	985
	613	22,242

28 TRADE AND OTHER PAYABLES

	As at	As at
	June 30,	December 31,
	2025	2024
	RMB'000	RMB'000
	(Unaudited)	(Audited)
Trade payables – third parties	109,563	99,961
Other payables – third parties	6,541	9,210
Payables for listing expenses in relation to global offering	–	1,486
VAT payables related to contract liabilities	4,994	6,188
Staff salaries and welfare payables	43,426	54,650
Accrued taxes other than income tax	4,280	5,765
Provision for outstanding litigations and claims (b)	716	4,313
Others	1,393	2,845
	170,913	184,418

- (a) The carrying amounts of trade and other payables are considered to be approximated their fair values, due to their short-term nature.
- (b) The Group was involved in an outstanding litigation. Based on the Group's litigation counsel's legal opinion, the directors of the Group made provision of RMB716,000 as at June 30, 2025 (December 31, 2024: RMB4,313,000).

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

28 TRADE AND OTHER PAYABLES (Continued)

Aging analysis of the trade payables based on purchase date at the end of June 30, 2025 are as follows:

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Up to 3 months	44,539	54,715
3 months to 6 months	17,271	14,141
6 months to 1 year	28,983	13,858
1 to 2 years	18,544	17,088
More than 2 years	226	159
	109,563	99,961

29 DEFERRED REVENUE

	As at June 30, 2025 RMB'000 (Unaudited)	As at December 31, 2024 RMB'000 (Audited)
Non-current		
Government grants (a)	7,402	7,402

(a) Deferred income mainly represents government grants received but yet to be recognised in other income.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

FOR THE SIX MONTHS ENDED JUNE 30, 2025

30 RELATED PARTY TRANSACTIONS

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operation decisions. Parties are also considered to be related if they are subject to common control. Members of key management and their close family members of the Group are also considered as related parties.

(a) Transactions with related parties

In the opinion of the Company's directors, the related party transactions were conducted in the ordinary course of business and based on terms mutually agreed by the underlying parties. Related party transactions of the Group during the six months ended June 30, 2025 include:

(i) Key management compensations

Key management includes directors (executive and non-executive) and senior management of the Company. The compensation paid or payable to key management for employee services is shown below:

	Six months ended June 30, 2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Wages, salaries and bonuses	8,043	10,974
Contributions to pension plans	305	260
Other social security costs, housing benefits and other employee benefits	321	278
Share-based payments	—	39,868
	8,669	51,380

As at June 30, 2025, compensation of RMB2,190,000 has not been paid to key management (for the six months ended June 30, 2024: RMB1,919,000).

31 CONTINGENCIES AND COMMITMENTS

(a) Contingencies

As at June 30, 2025, other than the outstanding litigations and claims disclosed in Note 28(b), there were no significant contingencies items for the Group.

(b) Commitments

As at June 30, 2025, the Group did not have any significant capital commitments.

32 EVENTS AFTER THE BALANCE SHEET DATE

Subsequent to June 30, 2025 and up to the date of this report, there is no material subsequent event.

Taimei
太美医疗科技

